文献速递乳腺癌

老年乳腺癌患者参与Alliance全身治疗试验的入组趋势:A151527方案

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.
PubMed 文献 · J Clin Oncol · 2016-12-19

该研究分析了1985-2012年Alliance for Clinical Trials in Oncology乳腺癌全身治疗试验中老年患者的入组情况。总体上17%的参与者年龄≥65岁;辅助试验中≥65岁患者入组几率随时间显著增加(OR 1.04,95%CI 1.04-1.05),而新辅助和转移试验中显著下降(OR 0.62,95%CI 0.58-0.67;OR 0.98,95%CI 0.97-1.00)。老年患者早期终止方案治疗更频繁(≥65岁50% vs <65岁35.9%)。

要点

  • 1985-2012年Alliance乳腺癌全身治疗试验中17%的参与者年龄≥65岁。
  • 辅助试验中≥65岁患者入组几率随时间增加(OR 1.04,95%CI 1.04-1.05)。
  • 新辅助和转移试验中≥65岁患者入组几率随时间下降(OR 0.62,95%CI 0.58-0.67;OR 0.98,95%CI 0.97-1.00)。

核心结论

  • 老年乳腺癌患者在合作组治疗试验中仍很大程度上代表性不足;辅助试验入组有所改善,但新辅助/转移试验入组恶化;需要新策略增加老年患者入组以改变证据基础。

研究设计与样本

  • 研究分析了1985-2012年Alliance for Clinical Trials in Oncology乳腺癌全身治疗试验中老年患者(年龄≥65岁和≥70岁)与年轻患者(年龄<65岁和<70岁)的入组情况,比较疾病特征和终止治疗原因,并使用逻辑回归以时间为函数建模年龄。

主要发现

  • 总体上17%的研究参与者年龄≥65岁;辅助、新辅助和转移试验中年龄≥65岁者分别约占15%、24%和24%,年龄≥70岁者分别约占7%、15%和13%。
  • 年龄≥65岁患者入组辅助试验的几率随时间显著增加(OR 1.04,95%CI 1.04-1.05),但新辅助和转移试验显著下降(OR 0.62,95%CI 0.58-0.67;OR 0.98,95%CI 0.97-1.00)。
  • 年龄≥70岁患者趋势相似,但仅在辅助和新辅助试验中具统计学显著性(OR 1.05,95%CI 1.04-1.07;OR 0.57,95%CI 0.52-0.62)。
  • 辅助研究中年龄≥65岁( vs <65岁)者平均受累淋巴结数更高、激素受体阴性肿瘤更多,但肿瘤大小相似。
  • 跨试验中年龄≥65岁者早期终止方案治疗更频繁(50% vs <65岁35.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Despite increasing awareness of accrual challenges, it is unknown if accrual of older patients to breast cancer treatment trials is improving. Methods We examined accrual of older patients to Alliance for Clinical Trials in Oncology systemic therapy breast cancer trials during 1985-2012 and compared disease characteristics and reasons for therapy cessation for older (age ≥ 65 years and ≥ 70 years) versus younger (age < 65 years and < 70 years) participants. To examine accrual trends, we modeled age as a function of time, using logistic regression. Results Overall, 17% of study participants were ≥ 65 years of age. Approximately 15%, 24%, and 24% of participants in adjuvant, neoadjuvant, and metastatic trials were age ≥ 65 years, and 7%, 15%, and 13% were age ≥ 70 years, respectively. The odds of a patient age ≥ 65 years enrolling significantly increased over time for adjuvant trials (odds ratio [OR] per year, 1.04; 95% CI, 1.04 to 1.05) but decreased significantly for neoadjuvant and metastatic trials (OR, 0.62; 95% CI, 0.58 to 0.67 and OR, 0.98, 95% CI, 0.97 to 1.00). Similar trends were seen for those age ≥ 70 years but these were statistically significant for adjuvant and neoadjuvant trials only (OR, 1.05, 95% CI, 1.04 to 1.07; and OR, 0.57, 95% CI, 0.52 to 0.62). In general, those age ≥ 65 years ( v those < 65 years) in adjuvant studies had a higher mean number of lymph nodes involved and more hormone receptor-negative tumors, although tumor sizes were similar. Early protocol treatment cessation was also more frequent in those age ≥ 65 years (50%) versus < 65 years (35.9%) across trials. Conclusion Older patients with breast cancer remain largely underrepresented in cooperative group therapeutic trials. We observed some improvement in accrual to adjuvant trials but worsening of accrual for neoadjuvant/metastatic trials. Novel strategies to increase accrual of older patients are critical to meaningfully change the evidence base for this growing patient population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Freedman RA, Foster JC, Seisler DK, et al. Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol. 2016. PMID: 27992272. doi:10.1200/JCO.2016.69.4182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。